PTK2B and neoplasm: The median survival probability in a cohort of patients with high gene expression versus low gene expression in tumor specimens was 12.94 months vs. 16.79 months (p = 0.009) for PTK2B and 12.58 months vs. 13.63 months (p = 0.0275) for PTK2.